Teva may grapple with questions about how its Austedo (deutetrabenzene) is worth the price premium over generic tetrabenzene while negotiating a “maximum fair price” with the US Centers for Medicare
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis
Novo Nordisk’s blockbuster semaglutide franchise – Rybelsus and Ozempic for type 2 diabetes and Wegovy for obesity – was included in the Centers for Medicare and Medicaid Services (CMS) list of 15 dru
Norwich Pharmaceuticals has seen denied its petition for the US Supreme Court to review litigation that has blocked its generic version of Bausch Health’s Xifaxan (rifaximin) from being approved by th